2024-02-03 06:57:03 ET
Summary
- Xencor demonstrates strong YoY revenue growth through achieved milestones with major industry partners.
- The strategic sale of royalty interests strengthens Xencor's balance sheet and provides flexibility for future strategic moves.
- Xencor's pipeline developments and clinical trials show a focus on promising therapies in oncology and autoimmune diseases.
Xencor ( XNCR ) is a clinical-stage biopharmaceutical firm that has shown a tactical aptitude for its financial capital and a prudent commitment to driving its best clinical schemes. The company’s 3Q23 financial results demonstrate strong YoY revenue growth mainly due to achieved milestones with major industry partners like Alexion ( ALXN ), Gilead ( GILD ), Janssen ( JNJ ), and Omeros ( OMER ). This tendency of revenue growth is also restrained by an increase in R&D expenses, which is a sign of the company’s dedication to the development of its clinical pipeline, which contains such promising candidates as vudalimab and XmAb541 ....
Read the full article on Seeking Alpha
For further details see:
Xencor: Standing Out With XmAb Technology